Ready for relapse: Molecule helps breast cancer cells to survive in the bone marrow

	Tweet

Patients who survive an initial diagnosis of breast cancer often succumb to the disease years later when the cancer shows up in a different part of the body. Now, scientists have identified key signals that support the long term survival of breast cancer cells after they have spread to the bone marrow. The research, published by Cell Press in the July issue of the journal Cancer Cell, may lead to development of treatment strategies that decrease the likelihood of breast cancer recurrence in the bone and other organs.

Metastasis, the ability of cancer cells to spread from the initial site of origin to other parts of the body, occurs frequently in breast cancer. Although it is clear that the majority of late-onset relapses after breast cancer arise in the bone, the mechanisms that contribute to cancer cell survival in the bone marrow environment are unknown.

“We sought to identify signaling pathways that support the survival of metastasized breast cancer cells and thereby extend the period during which metastasis may emerge after the diagnosis and removal of a breast tumor,” explains senior study author Dr. Joan Massague from the Cancer Biology and Genetics Programs at Memorial Sloan-Kettering Cancer Center and the Howard Hughes Medical Institute.

Dr. Massague and colleagues used a sophisticated gene profiling technique link specific signaling pathways with late-onset relapse after breast cancer. In an investigation of samples from over 600 breast tumors, the researchers discovered that activity of a cancer-related enzyme called Src was associated with late-onset bone metastasis. Interestingly, this link was independent of breast cancer subtype and was selective and specific for cell survival in the bone marrow.

The researchers went on to identify Src-regulated signaling molecules that were expressed in the bone marrow and promoted cell survival. Further, Src increased the resistance of metastasized breast cancer cells to a key cell death-inducing signal that was abundantly expressed in bone metastasis tissue. These results demonstrate that Src hyperactivity provides breast cancer cells with a superior ability to survive in the bone marrow.

“The link between Src-dependent signaling and metastatic cell survival provides mechanistic insights into metastasis latency, and suggests strategies to hasten the attrition of disseminated breast cancer cells,” concludes Dr. Massague. “Recently, a number of pharmacological Src inhibitors have been developed that may be worthy of consideration in this respect.”

###

The researchers Xiang H.-F. Zhang, Memorial Sloan-Kettering Cancer Center, New York, NY; Qiongqing Wang, Memorial Sloan-Kettering Cancer Center, New York, NY; William Gerald, Memorial Sloan-Kettering Cancer Center, New York, NY; Clifford A. Hudis, Memorial Sloan-Kettering Cancer Center, New York, NY; Larry Norton, Memorial Sloan-Kettering Cancer Center, New York, NY; Marcel Smid, Erasmus Medical Center Rotterdam, Josephine Nefkens Institute and Cancer Genomics Centre, Rotterdam, the Netherlands; John A. Foekens, Erasmus Medical Center Rotterdam, Josephine Nefkens Institute and Cancer Genomics Centre, Rotterdam, the Netherlands; and Joan Massague´ , Memorial Sloan-Kettering Cancer Center, New York, NY, Howard Hughes Medical Institute, Chevy Chase, MD.

Contact: Cathleen Genova

617-397-2802
Cell Press

RELATED STORIES:
Younger Breast Cancer Patients Have Greater Chance of Recurrence   Research Shows Biopsy of Recurrent Breast Cancer Can Alter Treatment   CSHL team identifies enzyme that is an important regulator of aggressive breast cancer development   New blood test picks up early breast cancer   Genes set scene for metastasis   Better marker for breast cancer may reduce need for second surgeries   Mastectomy Mystery: Why It’s a Choice When Cancer Isn’t Evident   Low income linked to poorer breast cancer survival   Ethnic Variations in Hormone Levels May Cause Differences in Breast Cancer Risk   Why are African American women more likely than whites to die from breast cancer?   Former KISS drummer: men get breast cancer too   New U.S. analysis backs annual breast screening   Lymphedema: Risk Reduction and Management Strategies   Breast Cancer Radiation Does Not Affect Women’s Immune System   WellPoint routinely targets breast cancer patients   New Subtype of Breast Cancer Responds to Targeted Drug   Big Bias In Who Gets Screened for Breast Cancer   Significant Advance in Treatment of Breast Cancer Reported   Statin Therapy Ineffective in Breast Cancer Prevention   Surgical breast biopsy not overused, study suggests   Study suggests newer breast cancer drug may protect heart   Malignant stem cells may explain why some breast cancers develop and recur

Comments

[ + Post Your Own ]

Now you're in the public comment zone. What follows is not Armenian Medical Network's stuff; it comes from other people and we don't vouch for it. A reminder: By using this Web site you agree to accept our Terms of Service. Click here to read the Rules of Engagement.

There are no comments for this entry yet. [ + Comment here + ]